Business / Finance

RSS

Courtagen, AGBL enter exclusive distribution agreement for clinical tests

Courtagen Life Sciences Inc. announced today they have signed an exclusive strategic distribution agreement with the Alliance Global Group (AGBL) to help clinicians in emerging markets diagnose and manage a number of genetically based disorders.

15 Nov 2012

EpiCept third quarter revenue increases to $0.9 million

EpiCept Corporation today reported a net loss for the three months ended September 30, 2012 of $1.1 million and a net loss for the nine months ended September 30, 2012 of $1.7 million.

14 Nov 2012

AspenBio Pharma provides clinical and business update for third quarter 2012

AspenBio Pharma, Inc., an in vitro diagnostic company, today provided a clinical and business update for the third quarter 2012. The Company reported it has started the hospital training phase of its pivotal U.S. clinical study and remains on track to initiate patient enrollment before the end of the year.

13 Nov 2012

Key areas of disease neglected by UK funding for infectious diseases

UK funding for infectious diseases research is neglecting some of the diseases that result in the highest rates of death and disability, according to an Article published Online First in The Lancet Infectious Diseases.

8 Nov 2012

EpiCept, Immune Pharmaceuticals enter definitive merger agreement

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation today announced that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013 and is subject to satisfaction of certain customary closing conditions, including the approval of a majority of EpiCept shareholders.

8 Nov 2012

Lower 3rd quarter earnings for Health Net, Humana - but optimism still reigns

Woodland Hills insurer Health Net Inc. said third-quarter net income plunged 71%, but its shares rose as the company resolved a dispute with California officials over reimbursement for government health programs. Health Net disappointed investors in August when it slashed its full-year profit outlook and reported higher-than-expected medical costs. On Monday, Chief Executive Jay Gellert ... cited a wide-ranging agreement with California healthcare officials as a major step forward.

7 Nov 2012

BioMimetic Therapeutics reports net loss of $4.6 million for third quarter 2012

BioMimetic Therapeutics, Inc. today reported its corporate highlights and financial results as of and for the three and nine months ended September 30, 2012. For the three months ended September 30, 2012, the Company reported a net loss of $4.6 million, or $0.16 per diluted share, compared to a net loss of $7.1 million, or $0.25 per diluted share, for the same period in 2011.

6 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Tornier third quarter 2012 sales increase to $58.0 million

Tornier N.V., a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, today reported its financial results for the third quarter ended September 30, 2012 and updated its fiscal 2012 financial outlook.

6 Nov 2012

Omega Protein third quarter revenues increase to $77.8 million

Omega Protein Corporation, a nutritional ingredient company and the nation's leading vertically integrated producer of omega-3 fish oil and specialty fish meal products, today reported financial results for the third quarter ended September 30, 2012.

6 Nov 2012

Depomed third quarter 2012 revenue increases to $33.3 million

Depomed, Inc. today reported financial results for the quarter and nine months ended September 30, 2012.

5 Nov 2012

Express Scripts reports net income of $391.4 million for third quarter 2012

Express Scripts announced 2012 third quarter net income of $391.4 million, or $0.47 per diluted share. Adjusted earnings per share, as detailed in Table 4 were $1.02 per diluted share for the third quarter.

5 Nov 2012

Affymetrix reports net loss of $17.9 million for third quarter 2012

Affymetrix, Inc., today reported its operating results for the third quarter of 2012. Total revenue for the quarter was $79.6 million, including approximately $17.6 million in revenue from eBioscience during the third quarter of 2012. This compares to total revenue of $64.0 million for the same period of 2011.

5 Nov 2012

Suicide rates in the US have increased sharply since the economic crisis began

Suicide rates in the US have risen sharply since the economic crisis took hold in 2007, warn the authors of Correspondence published Online First in The Lancet.

5 Nov 2012

Humana to acquire Metropolitan Health Networks

Humana Inc. and Metropolitan Health Networks, Inc. today announced that they have entered into a definitive agreement pursuant to which Humana will acquire Metropolitan in a transaction valued at approximately $850 million plus transaction costs.

5 Nov 2012

Health insurance news: Cigna earnings climb, small businesses drop coverage

The Bloomfield, Conn., managed-care company significantly boosted its full-year adjusted earnings guidance after posting better results than Wall Street expected. The company Thursday also announced a restructuring plan that includes reducing the size of its global workforce about 4%, affecting 1,300 workers amid a mix of layoffs and hiring. Cigna continued a streak of "beat and raise" third-quarter reports for large health insurers.

3 Nov 2012

Torchmark closes previously announced purchase of Family Heritage

Torchmark Corporation is pleased to announce that it closed the previously announced purchase of Family Heritage Life Insurance Company of America (Family Heritage), a privately-held supplemental health insurance provider, on November 1, 2012 for approximately $232 million, subject to final post-closing adjustments.

3 Nov 2012

International Bipolar Foundation announces acquisition of National Bipolar Foundation

International Bipolar Foundation (IBPF) is pleased to announce the acquisition of the National Bipolar Foundation (NBF). NBF was founded by F. Marc Kullman in 2005. After being diagnosed in 1997 with Bipolar Disorder, he was determined to become a spokesperson for the disease, with hopes of eradicating the stigma associated with the illness.

3 Nov 2012

University of Cambridge forms new spin-out company to supply hIPSC-derived cells

The potential therapeutic applications of stem cells - such as regenerating damaged tissues or organs - have generated a great deal of interest over the past decade. While these types of applications are exciting, it is a long journey from lab to clinic. The most immediate impact of stem cells on human health will most likely come from their use in the development of new drugs.

3 Nov 2012

New image guided instrumentation for DePuy Synthes Spine’s leading spine systems

DePuy Synthes Spine announced new image guided instrumentation for two of its leading spine systems and has entered into a new partnership agreement with Brainlab, enabling both companies to offer integrated surgical navigation and imaging solutions.

2 Nov 2012